# Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells

**Jian-Jun Liu[1], Åke Nilsson[2], Stina Oredsson[3], Vladimir Badmaev[4], Wan-Zhou Zhao[5] and Rui-Dong Duan[1,6]**

[1]Cell Biology B, Biomedical Center, B11, Lund University, Lund, Sweden, [2]Institute of Medicine, Lund University Hospital, Lund, Sweden, [3]Department of Animal Physiology, Lund University, Lund, Sweden, [4]Sabinsa Corporation, Piscataway, New Jersey, USA and [5]Department of Pharmacology, Chinese Academy of Medical Sciences, Beijing, China

[6]To whom correspondence should be addressed
Email: rui-dong.duan@med.lu.se

**Boswellic acids are the effective components of gum resin of *Boswellia serrata*, which has anti-inflammatory properties. Recent studies on brain tumors and leukemic cells indicate that boswellic acids may have antiproliferative and apoptotic effects with the mechanisms being not studied in detail. We studied their antiproliferative and apoptotic effects on colon cancer cells and the pathway leading to apoptosis. HT-29 cells were treated with β-boswellic acid (BA), keto-β-boswellic acid (K-BA) and acetyl-keto-β-boswellic acid (AK-BA), respectively. Apoptosis was determined by flow cytometry, by cytoplasmic DNA–histone complex and the activity of caspase-3. The cleavage of poly-(ADP-ribose)-polymerase (PARP) and expression of Fas were examined by western blot. Specific caspase inhibitors, polyclonal Fas antibody, and antagonistic Fas antibody ZB4 were employed to elucidate apoptotic pathways. DNA synthesis and cell viability were examined. Both K-BA and AK-BA increased cytoplasmic DNA–histone complex dose-dependently and increased pre-$G_1$ peak in flow cytometer analysis, with the effects of AK-BA being stronger than K-BA. BA only increased the formation of DNA–histone complex at a high concentration. K-BA and AK-BA increased caspase-8, caspase-9 and caspase-3 activities accompanied by cleavage of PARP. The effects of AK-BA on formation of cytoplasmic DNA histone and on caspase-3 activation were 3.7- and 3.4-fold, respectively, more effective than those induced by camptothecin. The apoptosis induced by AK-BA was inhibited completely by caspase-3 or caspase-8 inhibitor and partially by caspase-9 inhibitor. ZB4 blocked exogenous Fas ligand-induced apoptosis, but had no effect on AK-BA-induced apoptosis. AK-BA had no significant effect on expression of Fas. Apart from apoptotic effect, these acids also inhibited [3H]thymidine incorporation and cell viability to different extent. In conclusion, boswellic acids, particularly AK-BA and K-BA have antiproliferative and apoptotic effects in human HT-29 cells. The apoptotic effect is mediated via a pathway dependent on caspase-8 activation but independent of Fas/FasL interaction.**

**Abbreviations:** AK-BA, acetyl-keto-β-boswellic acid; BA, β-boswellic acid; COX, cyclooxygenase; DMSO, dimethyl sulfoxide; K-BA, keto-β-boswellic acid; MAP, mitogen activated protein; PARP, poly-(ADP-ribose)-polymerase.

## Introduction

The gum resin of *Boswellia serrata*, a kind of deciduous tree grown in the dry part of China and India, has been used for the treatment of inflammatory and arthritic diseases from the very beginning of human civilization (1). The pentacyclic triterpenic acids, named boswellic acids, in the gum resin of the tree are the main constituents for its anti-inflammatory property (2,3). Suppression of leukotriene synthesis via inhibiting 5-lipoxygenase is considered the main mechanism underlying their anti-inflammatory effect. Nowadays, boswellic acids have been regarded as specific, non-redox inhibitors of 5-lipoxygenase as they do not affect 12-lipoxygenase and cyclooxygenase (COX) activities (3–5). In addition, boswellic acids also inhibit leukocyte elastase, which may also contribute to their anti-inflammatory properties (6,7).

Besides the anti-inflammatory effects, several studies on brain tumors and leukemic cells indicated that boswellic acids might have anticancer effects (8–11). Very recently, their potential roles in the diseases of intestinal tract have started to draw attention, and the acids have been used in clinical trials or experimental animal models for the treatment of Crohn's disease, ulcerative colitis and ileitis (12–14), and have been shown to inhibit azoxymethane-induced formation of aberrant crypt foci in the colon of mice (15).

In the present study, the apoptotic and antiproliferative effects of β-boswellic acid (BA), keto-β-boswellic acid (K-BA) and acetyl-keto-β-boswellic acid (AK-BA), three main constitutes of *B.serrata* extract, were studied in colon cancer HT-29 cells. The signal transduction pathway underlying boswellic acid-induced apoptosis was closely investigated.

## Materials and methods

### Materials

HT-29 cells were obtained from American Tissue Culture Collection (Rockville, MD). The Cell Death Detection kit and the Cell Proliferation Reagent 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazoliol]-1,3-benzene disulfonate (WST-1) were obtained from Roche Diagnostics GmbH (Mannheim, Germany). [3H]Thymidine was purchased from DuPont Corporation (Cambridge, MA). Caspase-3 substrate Asp-Glu-Val-Asp-*p*-nitroanilide (DEVD-pNA) was obtained from Oncogene Research Product (Cambridge, MA). Caspase-8 substrate (Ac-Ile-Glu-Thr-Asp-pNA), caspase-9 substrate (Ac-Leu-Glu-His-Asp-pNA) and antagonistic Fas antibody clone ZB4 were purchased from Upstate Biotechnology (Lake Placid, NY). Polyclonal antibody of Fas was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and polyclonal antibody of β-actin was from Chemicon (Hampshire, UK). Caspase-3 inhibitor (Z-DEVD-FMK), caspase-8 inhibitor (Z-IETD-FMK) and caspase-9 inhibitor (Z-LEHD-FMK) were obtained from R & D Systems Europe (Abingdon, UK). An antibody against poly-(ADP-ribose)-polymerase (PARP) was purchased from Boehringer Mannheim (Bromma, Sweden). Human recombinant SuperFas ligand was obtained from Alexis Corporation (San Diego, CA). BA, K-BA and AK-BA (purity 98% by HPLC) were provided by Sabinsa Corporation (Piscataway, NJ). Camptothecin was purchased from Sigma Co. (Stockholm, Sweden).

### Cell culture

HT-29 cells were cultured in RPMI-1640 medium with L-glutamine, containing 100 IU/ml penicillin, 10 µg/ml streptomycin and 10% (v/v) heat-inactivated fetal calf serum and maintained at 37°C in an incubator containing 95% air

and 5% $CO_2$. BA, K-BA and AK-BA were dissolved in ethanol and camptothecin in dimethyl sulfoxide (DMSO) as 100 mM stock solutions and stored at −20°C. The cells were harvested at ~80% confluence and subcultured in RPMI-1640 medium. After incubation overnight, the cells were treated with the agents tested. Medium containing 0.1% ethanol or DMSO was used as a control.

*Apoptosis detection by ELISA*

Several methods were used to detect apoptosis. The first one is based on a quantification of the enrichment of mono- and oligo-nucleosomes in the cytoplasm by Cell Death Detection ELISA kit. Briefly, $1 \times 10^4$ cells in 100 ml of RPMI-1640 medium were incubated with boswellic acids or camptothecin for 24 h. The cells were lysed and centrifuged. The supernatant containing the cytoplasmic histone-associated DNA fragments was transferred to a microplate coated with streptavidin, and then reacted with a mixture of the anti-histone antibodies labeled with biotin, and anti-DNA antibodies coupled with peroxidase. The substrate of peroxidase was thereafter added and development of the color was read photometrically at 405 nm against 490 nm as background. The specific enrichment of mono- and oligo-nucleosomes released into the cytoplasm was expressed as enrichment factor compared with the control.

*Assay apoptosis and cell cycle phase distribution by flow cytometry*

Cells ($3 \times 10^6$) were treated with 100 mM BA, K-BA or AK-BA for 24 h. The cells were then resuspended in ice-cold 70% ethanol and stored at −20°C until analysis. The cellular DNA was stained with PBS containing 100 μg/ml propidium iodide, 0.6% Nonidet P-40 and 100 μg/ml RNase A. Flow cytometric analysis was performed in an Ortho Cytoron Absolute Flow Cytometer (Ortho Raritan, NJ) as described previously (16). The cell cycle phase distribution was analyzed using the Multi2D and MultiCycle software program.

*Assay activities of caspase-3, caspase-8 and caspase-9*

Caspase activities were assayed using their specific substrates as described (17). Briefly, $3 \times 10^6$ cells were incubated with RPMI-1640 medium containing boswellic acids or camptothecin for 24 h. The cells were lyzed in 80 μl of ice-cold lysis buffer containing 50 mM HEPES, 100 mM NaCl, 0.1% CHAPS, 1 mM DTT and 0.1 mM EDTA, pH 7.4 and put on ice for 5 min, followed by centrifugation at 10 000 *g* for 15 min at 4°C. Twenty microliters of the supernatant was added to 100 μl assay buffer containing 50 mM HEPES, 100 mM NaCl, 0.1% CHAPS, 10 mM DTT, 0.1 mM EDTA, 10% glycerol, pH 7.4. Ten microliters of caspase substrate were then added in the reaction system to final concentration of 0.2 mM. The cleavage of the substrate was followed spectrophotometrically at 405 nm and the activities were calculated according to the instruction of the manufacturer.

*Western blot*

For identification of PARP, $3 \times 10^6$ cells were mixed with 100 μl 25 mM Tris–HCl buffer pH 8.0, containing 50 mM glucose, 10 mM EDTA, and 1 mM PMSF, and 50 μl of 50 mM Tris–HCl buffer, pH 6.8, containing 6 M urea, 6% 2-mercaptoethanol, 3% SDS and 0.003% bromphenolblue. The extract was sonicated for 60 s and incubated for 15 min at 65°C before loading. Fifty micrograms of cellular proteins were subject to 10% PAGE, followed by transferring to nitrocellulose membrane electrophoretically. After washing and blocking, the membrane was incubated with PARP antibody (1:2000) for 2 h, and then with biotinylated goat anti-rabbit antibody for 1.5 h. The second antibody was bound to a streptavidin-biotinylated alkaline phosphatase (AP) complex. Color development was proceeded with a Bio-Rad AP conjugate substrate kit (Hercules, CA). For identification of Fas, the cells were lysed in 50 mM Tris buffer containing 2 mM EDTA, 10 mM taurocholate, 1 μg/ml of leupeptin, 1 μg/ml of aprotinin, 1 mM PMSF and 0.5 mM DTT, followed by sonication for 10 s. Fifty micrograms of protein were subject to 10% SDS–PAGE and transferred to nitrocellulose membrane in a similar way as for PARP. After blocking with 5% dry milk for 4 h, the membrane was then blotted with anti-Fas antibody (1:250). After washing, the second antibody conjugated with alkaline phosphatase was added and the color development procedure was the same as described for PARP. To confirm that an equal amount of proteins was loaded, a parallel western blot was performed in both cases mentioned above. The membranes were blotted with anti-β-actin at 1:10 dilution, according to the instructions of the company.

*Treatment with caspase inhibitors and antagonistic Fas antibody*

To observe the effects of specific caspase inhibitors on boswellic acid-induced apoptosis, Z-DEVD-FMK, Z-IETD-FMK and Z-LEHD-FMK were dissolved in DMSO as 20 mM stock solution and added to the culture medium to a final concentration of 50 μM. After 2 h pre-incubation, AK-BA was added to a final concentration of 100 μM, followed by an additional incubation for 24 h. For the study with antagonistic Fas antibody, the cells were pre-incubated with ZB4 (3 μg/ml) for 2 h. AK-BA or SuperFas ligand was added to a final



**Fig. 1.** Apoptotic effects of BA, K-BA and AK-BA on HT-29 cells. The cells were treated with BA, K-BA or AK-BA of different concentrations for 24 h. Cytoplasmic DNA–histone complex was measured by ELISA. Experiments were performed in triplicate of three separate experiments and results are expressed as mean ± standard deviation. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ compared with control (0 concentration).

concentration of 100 μM and 1 μg/ml, respectively, followed by a further incubation for 24 h. The changes of AK-BA induced apoptosis in the presence of these inhibitors were determined as described.

*Assay of cell viability and DNA synthesis*

Cell viability was assayed by determination of the cleavage of tetrazolium salt (WST-1) to formazan by mitochondrial dehydrogenases. The amount of formazan formed is proportional to the viable cell numbers. The cells ($2 \times 10^4$) in 200 μl medium were incubated with boswellic acids of different concentrations in a 96 well microplate for 24 h and 20 μl WST-1 was then added in each well. After incubation for 1 h, the production of formazan was read photometrically at 405 nm against 620 nm as a background. The results were expressed as percentage of the control.

The DNA synthesis was measured by [³H]thymidine incorporation. The cells were treated with boswellic acids of different concentrations for 24 h in a microplate ($2 \times 10^4$ cells/well in 200 μl medium). After incubation, 0.5 μCi of [³H]thymidine (diluted in 10 ml medium) was added to each well followed by 4 h incubation. The cells were washed with cold PBS three times and then incubated with 10% trichloroacetic acid for 20 min at 4°C. After fixing with methanol for 10 min, the cells were lysed by addition of 200 μl lysis buffer containing 0.25 M sodium hydroxide and 0.1% sodium dodecyl sulfate. An aliquot of 50 μl of the lysate was taken for liquid scintillation counting. DNA synthesis was expressed as percentage of control.

*Statistical analysis*

The results were presented as mean ± standard deviation. The data were analyzed by non-paired Student *t*-test and $P < 0.05$ was considered statistically significant.

## Results

*Apoptosis detected by ELISA*

As shown in Figure 1, both K-BA and AK-BA dose dependently increased the cytoplasmic DNA–histone complex in HT-29 cells. The effect of AK-BA was stronger than that of K-BA, and the effect of BA occurred only at the highest concentration. Incubation with 100 μM BA and K-BA for 24 h increased the levels of cytoplasmic DNA–histone complex to ~2- and 3-fold of control, whereas incubation with 50 μM AK-BA increased the enrichment factor to 6-fold of the control. Further increasing the concentration of AK-BA to 100 μM did not enhance its apoptotic effect significantly.

*Apoptosis measured by flow cytometry*

After incubation with K-BA and A-K-BA of 100 μM for 24 h, the number of apoptotic cells increased significantly as

Fig. 2. Apoptotic effect of boswellic acids on HT29 cells assayed by flow cytometry. HT-29 cells were treated with 100 µM BA, K-BA or AK-BA for 24 h. DNA was stained with propidium iodide. The figure shows the profile of control cells (**A**), BA-treated cells (**B**), K-BA-treated cells (**C**) and A-K-BA-treated cells (**D**).



Fig. 4. Cleavage of PARP detected by western blot. HT-29 cells were treated with 100 µM AK-BA for 24 h. Fifty micrograms of cell-free extract were subjected to 10% SDS–PAGE and the proteins were transferred to nitrocellulose membrane electrophoretically. The membrane was blotted with anti-PARP antibody first and then a secondary antibody coupled with alkaline phosphatase. Color development was proceeded with a Bio-Rad amplified alkaline phosphatase Immun-Blot kit (upper panel). In the lower panel, a parallel experiment was performed and the membrane was blotted with anti-actin antibody.



Fig. 3. Changes in the activities of caspase-3, caspase-8 and caspase-9 in HT-29 cells after treatment with boswellic acids. The cells were treated with 100 µM BA, K-BA and AK-BA for 24 h. The cytosolic fraction was extracted and caspase activities were measured. Experiments were performed in triplicate in three separate experiments and results are expressed as mean ± standard deviation. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ compared with control.

demonstrated by the sub-$G_1$ peak (Figure 2C and D). The apoptotic effect of AK-BA was stronger than that of K-BA, as AK-BA induced a much larger proportion of sub-$G_1$ cells. Flow cytometry did not show a significant increase of sub-$G_1$ peak for BA (Figure 2B) at the same concentration.

*Changes in caspase activities*

The changes of three types of caspase activities are shown in Figure 3. After treatment with 100 µM K-BA and AK-BA, the activity of caspase-3 increased ~300 and 250%, respectively, compared with control. They also increased the activities of caspase-8 by 88 and 275%, respectively, and those of caspase-9 by 137 and 262%, respectively. BA at 100 µM concentration did not show significant stimulatory effect on the activities of all three kinds of caspases.

*Cleavage of PARP*

It is well known that PARP, the zinc-dependent DNA binding protein that specifically recognizes DNA strand breaks, is cleaved by caspase-3, and the cleavage of PARP is regarded as a specific marker of apoptosis (18). To further confirm the apoptotic effects of boswellic acids in HT29 cells, a western blot was performed to examine the cleavage of PARP by AK-BA. After treating the cells with 100 µM AK-BA, the content of the intact form (113 kDa) of PARP was decreased and its 89 kDa cleaved fragment was increased (Figure 4, upper panel). No changes could be identified when the samples were blotted by anti-actin (Figure 4, lower panel).

*Comparison of the apoptotic effect of AK-BA with camptothecin*

To evaluate the efficiency of the effects of boswellic acid on HT29 cells, the formation of DNA–histone complex and the activation of caspase-3 induced by AK-BA were compared with those induced by camptothecin. As shown in Figure 5, at 50 µM, both effects of AK-BA were >3-fold greater than those induced by camptothecin.

*Effect of caspase inhibitors and antagonistic Fas antibody on boswellic acid-induced apoptosis*

In order to elucidate which pathway was predominant for boswellic acid-induced apoptosis, specific caspase inhibitors and antagonistic Fas antibody ZB4 were employed. As shown in the upper panel of Figure 6, both caspase-3 and caspase-8 inhibitors completely blocked AK-BA-induced apoptosis while the inhibitor of caspase-9 only partially inhibited it. As caspase-8 is closely linked to a signal transduction pathway initiated by interaction of Fas/FasL, we examined whether activation of Fas would be important in mediating the effect of boswellic acids. As shown in the lower panel of Figure 6, pre-treatment with ZB4 did no have any inhibitory effect on boswellic acid-induced apoptosis, although it did completely block the apoptosis induced by exogenous Fas ligand. We then further studied whether the expression of Fas could be increased by boswellic acids. As shown in the upper panel of Figure 7, stimulating the cells with AK-BA or BA at 50 or 100 µM for 24 h had no significant effect on the levels of Fas in the cells. The negative effect were strengthened by the similar levels of β-actin in the samples as demonstrated in the lower panel of Figure 7.

**Fig. 5.** Comparison of the effects of AK-BA on apoptosis and caspase-3 activation with camptothecin. The cells were treated with 50 µM AK-BA or 50 µM camptothecin for 24 h. The formation of DNA–histone complex (upper panel) and the activity of caspase-3 (lower panel) were determined. Experiments were performed in triplicate in three separate experiments and results are mean ± standard deviation. **$P < 0.01$, ***$P < 0.001$ compared with control.

*Inhibition of DNA synthesis and cell viability by boswellic acids*

Figure 8 demonstrated that BA, K-BA and AK-BA inhibited the [³H]thymidine incorporation in a dose-dependent manner (upper panel) with the effect of AK-BA being strongest, followed by K-BA and BA. At 50 µM, AK-BA inhibited DNA biosynthesis by 53%, whereas K-BA and BA decreased it by 33 and 25%, respectively. When the cell viability was determined (Figure 8, lower panel), AK-BA strongly inhibited cell viability in a dose-dependent manner. At 100 µM AK-BA reduced the cell viability by 50%, whereas BA and K-BA only slightly inhibited the viability by 15%. These effects are not statistically significant.

## Discussion

In the present study, we found that boswellic acids have antiproliferative and apoptotic effects on HT29 colon cancer cells. The apoptotic effect of AK-BA was demonstrated by



**Fig. 6.** Effects of caspase inhibitors (upper panel) and antagonistic Fas antibody ZB4 (lower panel) on AK-BA-induced apoptosis. HT-29 cells were pre-treated with 50 µM caspase-3 (Cp3), caspase-8 (Cp8), caspase-9 (Cp9) inhibitors or 3 µg/ml ZB4 for 2 h. AK-BA or Fas ligand (FasL) was then added to a final concentration of 100 µM or 1 µg/ml, respectively. Experiments were performed in triplicate in three separate experiments and results are expressed as mean ± standard deviation. ***$P < 0.001$ compared with effect of AK-BA alone, **$P < 0.05$ compared with effect of FasL.



**Fig. 7.** Effect of AK-BA on Fas expression. The cells were treated with 50 and 100 µM of BA or AK-BA for 24 h. The cell-free extract (50 µg) was subjected to 10% SDS–PAGE and transferred to nitrocellulose membrane, which was blotted with anti-Fas antibody (upper panel) or anti-actin (lower panel), respectively. Lanes A and D, control; lanes B and C, samples treated with 50 and 100 µM BA, respectively; lanes E and F, samples treated with 50 and 100 µM AK-BA, respectively.

the increased cytoplasmic DNA–histone complex, and the increased sub-G₁ peak by flow cytometric analysis. The apoptotic effect was also confirmed by the activation of caspase-3,

**Fig. 8.** Effects of BA, K-BA and AK-BA on DNA synthesis (upper panel) and cell viability (lower panel). HT-29 cells were treated with BA, K-BA or AK-BA of different concentrations for 24 h. DNA synthesis was measured by [³H]thymidine incorporation and cell viability was assayed by the cleavage of WST-1 reagent. Experiments were performed in triplicate in three separate experiments and results are expressed as mean ± standard deviation. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ compared with control (0 concentration).

the executor of apoptosis, and cleavage of PARP, another specific marker of apoptosis.

Apoptotic effect is considered to be one of the important properties for many anticancer drugs. Apoptosis occurs via two major different activation pathways in principle (19,20). One pathway involves changes in mitochondrial transmembrane potential, leading to the release of cytochrome c. Cytochrome c then binds the apoptosis activating factor 1 and procaspase-9, resulting in the activation of caspase-9 by proteolytic cleavage. The other pathway starts with death receptor ligation or Fas/FasL interaction, followed by oligomerization of the receptor, recruitment of Fas-associated death domain protein (FADD), and activation of caspase-8 (21). Both caspase-9 and caspase-8 are defined as initiator caspases

and can in turn activate caspase-3, the executor of apoptosis (22,23). Recently, it was found that the cross communication exists between the two pathways, as caspase-8 may activate caspase-9 via Bid, a member of bcl-2 family (24). Although the apoptotic effect of boswellic acids were reported previously in glioma and leukemic cells, the caspase cascade activated by the acids leading to apoptosis has not been studied (9,11). In the present work, we demonstrated for the first time that the activities of caspase-3, caspase-8 and caspase-9 were activated by boswellic acids, indicating that both death receptor-related apoptotic pathway and the mitochondria-related pathway were activated. When specific inhibitors were employed, however, we found that either specific caspase-8 or caspase-3 inhibitor completely blocked the boswellic acid-induced apoptosis, while the caspase-9 inhibitor only partially inhibited it. These findings imply that apoptosis induced by boswellic acids in HT-29 cells is initiated by a pathway involving the activation of caspase-8, leading to the activation of caspase-3 and the cleavage of PARP. The activation of caspase-9 is probably a secondary consequence of the activation of caspase-8 through the cross communication between the two apoptotic pathways (25,26).

It is well known that activation of caspase-8 is closely linked to the death receptor Fas (also known as APO-1 or CD 95) that belongs to the tumor necrosis factor/nerve growth factor receptor family (26,27). In colon cancer, the Fas signaling pathway via Fas/FasL interaction was indicated to be involved in liver metastasis, counterattack of tumor-immune conflict and cytotoxic drug-induced apoptosis, although its exact role was still controversial (28–30). In the present study, we found that Fas/FasL interaction was not critical in boswellic acid-induced apoptosis, because antagonistic Fas antibody ZB4 failed to inhibit boswellic acid-induced apoptosis at a dose that completely blocked the apoptosis induced by FasL. The effect of boswellic acids may neither affect the levels of Fas, since western blot failed to identify any increase in Fas after BA and AK-BA stimulation. It is therefore reasonable to propose that boswellic acid induced apoptosis in HT29 cells is mediated by mechanisms downstream of Fas/FasL interaction, such as Fas clustering, recruitment of FADD, or enhancing the cleavage of procaspase-8. These possibilities have been recently indicated in studies with several other anticancer drugs (31–33).

Boswellic acids are inhibitors of 5-lipoxygenase, and the inhibitory effect has been demonstrated in both intact cells and in the cell-free system (3,5,34). It was reported that MK886, the inhibitor of 5-lipoxygenase activating protein triggered apoptosis in both prostate and breast cancer cells (35,36). Thus, the inhibitory effects of boswellic acid on 5-lipoxygenase may be responsible for its apoptotic properties. However, in some leukemic cell lines such as HL-60 and CCRF-CEM cells, which do not express 5-lipoxygenase mRNA constitutively, apoptotic and antiproliferative effect of boswellic acids could still be observed, indicating that the blockade of 5-lipoxygenase may not be the only mechanism underlying its apoptotic effect (37). Boswellic acids were reported to inhibit topoisomerases (37,38), and to increase the intracellular calcium and activity of mitogen activated protein (MAP) kinase in human isolated leukocyte (39). Calcium mobilization has been reported to be linked to death receptor and caspase-8 activation (40,41). Putting together, to find out the relationship between 5-lipoxygenase inhibition, topoisomerase inhibition,

calcium mobilization, MAP kinase activation and caspase-8 activation are interesting topics for further investigation.

The anticancer effects of boswellic acids varied with the type of the acids. K-BA and AK-BA had significant effects on apoptosis. BA seems only effective in the inhibition of DNA biosynthesis. In terms of either antiproliferative or apoptotic effects among the boswellic acids tested, AK-BA was the most effective one, followed by K-BA and BA. Considering the structure of various boswellic acids, the keto group might be important for apoptotic properties of the acids and the presence of acetyl group may strongly enhance its apoptotic effects.

Our findings that boswellic acids have antiproliferative and apoptotic effects in colon cancer cells may have clinical implications. The chemopreventive effect of NSAIDs such as sulindac on colon cancer has been well documented in the past two decades (42,43). However, blockade of COX by NSAIDs, especially the blockade of COX-1, could cause multiple severe side effects such as the bleeding in the intestinal tract and impairment of renal function (44,45). In contrast, boswellic acids did not inhibit COX and their clinical safety has been demonstrated in the treatment of Crohn's disease, ulcerative colitis and bronchial asthma (4,12,14,46). Because of the low toxicity, the acids can be given orally or intrarectally in a high dose. In addition, we reported recently that K-BA and AK-BA also induced apoptosis in HepG2 cells (47), a cell line that is better differentiated than HT29 cells (48). Thus, boswellic acid may affect cells of different degrees of differentiation. Finally, AK-BA was found to be ~3-fold more effective than camptothecin, a compound that has a similar inhibitory effect on topoisomerase as boswellic acid. Derivatives of camptothecin are normally prescribed in colorectal cancer cases that have not responded to standard chemotherapy treatment. Judged from these aspects above, whether boswellic acids can be promising candidates for the chemoprevention of colon cancer might be an interesting topic for further investigation.

## Acknowledgements

## References

1. Han,R. (1994) Highlight on the studies of anticancer drugs derived from plants in China. *Stem Cells*, **12**, 53–63.
2. Reddy,G.K., Chandrakasan,G. and Dhar,S.C. (1989) Studies on the metabolism of glycosaminoglycans under the influence of new herbal anti-inflammatory agents. *Biochem. Pharmacol.*, **38**, 3527–3534.
3. Safayhi,H., Mack,T., Sabieraj,J., Anazodo,M.I., Subramanian,L.R. and Ammon,H.P. (1992) Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. *J. Pharmacol. Exp. Ther.*, **261**, 1143–1146.
4. Ammon,H.P., Safayhi,H., Mack,T. and Sabieraj,J. (1993) Mechanism of antiinflammatory actions of curcumine and boswellic acids. *J. Ethnopharmacol.*, **38**, 113–119.
5. Safayhi,H., Sailer,E.R. and Ammon,H.P. (1995) Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. *Mol. Pharmacol.*, **47**, 1212–1216.
6. Safayhi,H., Rall,B., Sailer,E.R. and Ammon,H.P. (1997) Inhibition by boswellic acids of human leukocyte elastase. *J. Pharmacol. Exp. Ther.*, **281**, 460–463.
7. Kapil,A. and Moza,N. (1992) Anticomplementary activity of boswellic acids—an inhibitor of C3-convertase of the classical complement pathway. *Int. J. Immunopharmacol.*, **14**, 1139–1143.
8. Shao,Y., Ho,C.T., Chin,C.K., Badmaev,V., Ma,W. and Huang,M.T. (1998) Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. *Planta Med.*, **64**, 328–331.
9. Glaser,T., Winter,S., Groscurth,P., Safayhi,H., Sailer,E.R., Ammon,H.P., Schabet,M. and Weller,M. (1999) Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. *Br. J. Cancer*, **80**, 756–765.
10. Winking,M., Sarikaya,S., Rahmanian,A., Jodicke,A. and Boker,D.K. (2000) Boswellic acids inhibit glioma growth: a new treatment option? *J. Neurooncol.*, **46**, 97–103.
11. Jing,Y., Nakajo,S., Xia,L., Nakaya,K., Fang,Q., Waxman,S. and Han,R. (1999) Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. *Leuk. Res.*, **23**, 43–50.
12. Gerhardt,H., Seifert,F., Buvari,P., Vogelsang,H. and Repges,R. (2001) Therapy of active Crohn disease with Boswellia serrata extract H 15. *Z. Gastroenterol.*, **39**, 11–17.
13. Gupta,I., Parihar,A., Malhotra,P., Singh,G.B., Ludtke,R., Safayhi,H. and Ammon,H.P. (1997) Effects of *Boswellia serrata* gum resin in patients with ulcerative colitis. *Eur. J. Med. Res*, **2**, 37–43.
14. Krieglstein,C.F., Anthoni,C., Rijcken,E.J., Laukotter,M., Spiegel,H.U., Boden,S.E., Schweizer,S., Safayhi,H., Senninger,N. and Schurmann,G. (2001) Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from *Boswellia serrata* resin, attenuates experimental ileitis. *Int. J. Colorectal. Dis.*, **16**, 88–95.
15. Huan,M.T., Badmaev,V., Ding,Y., Liu,Y., Xie,J.G. and Ho,C.T. (2000) Anti-tumor and anti-carcinogenic activities of triterpenoid, beta-boswellic acid. *Biofactors*, **13**, 225–230.
16. Fredlund,J.O., Johansson,M., Baldetorp,B. and Oredsson,S.M. (1994) Abnormal DNA synthesis in polyamine deficient cells revealed by bromodeoxyuridine-flow cytometry technique. *Cell Prolif.*, **27**, 243–256.
17. Liu,J-J., Wang,J-Y., Hertervig,E., Cheng,Y., Nilsson,Å. and Duan,R-D. (2000) Activation of neutral sphingomyelinase participates in ethanol-induced apoptosis in Hep G2 cells. *Alcohol Alcoholism*, **35**, 569–573.
18. Nicholson,D.W., Ali,A., Thornberry,N.A., Vaillancourt,J.P., Ding,C.K., Gallant,M., Gareau,Y., Griffin,P.R., Labelle,M. and Lazebnik,Y.A. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. *Nature*, **376**, 37–43.
19. Green,D.R. (1998) Apoptotic pathways: the roads to ruin. *Cell*, **94**, 695–698.
20. Green,D.R. and Reed,J.C. (1998) Mitochondria and apoptosis. *Science*, **281**, 1309–1312.
21. Ashkenazi,A. and Dixit,V.M. (1998) Death receptors: signaling and modulation. *Science*, **281**, 1305–1308.
22. Stennicke,H.R. and Salvesen,G.S. (1998) Properties of the caspases. *Biochim. Biophys. Acta*, **1387**, 17–31.
23. Stennicke,H.R., Jurgensmeier,J.M., Shin,H. *et al* (1998) Pro-caspase-3 is a major physiologic target of caspase-8. *J. Biol. Chem.*, **273**, 27084–27090.
24. Zha,J., Weiler,S., Oh,K.J., Wei,M.C. and Korsmeyer,S.J. (2000) Posttranslational *N*-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. *Science*, **290**, 1761–1765.
25. Zha,X., Pierini,L.M., Leopold,P.L., Skiba,P.J., Tabas,I. and Maxfield,F.R. (1998) Sphingomyelinase treatment induces ATP-independent endocytosis. *J. Cell. Biol.*, **140**, 39–47.
26. Li,H., Zhu,H., Xu,C.J. and Yuan,J. (1998) Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis. *Cell*, **94**, 491–501.
27. Itoh,N., Yonehara,S., Ishii,A., Yonehara,M., Mizushima,S., Sameshima,M., Hase,A., Seto,Y. and Nagata,S. (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. *Cell*, **66**, 233–243.
28. Yoong,K.F., Afford,S.C., Randhawa,S., Hubscher,S.G. and Adams,D.H. (1999) Fas/Fas ligand interaction in human colorectal hepatic metastases: a mechanism of hepatocyte destruction to facilitate local tumor invasion. *Am. J. Pathol.*, **154**, 693–703.
29. Xu,X., Fu,X.Y., Plate,J. and Chong,A.S. (1998) IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. *Cancer Res.*, **58**, 2832–2837.
30. Tillman,D.M., Petak,I. and Houghton,J.A. (1999) A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. *Clin. Cancer Res.*, **5**, 425–430.
31. Shao,R.G., Cao,C.X., Nieves-Neira,W., Dimanche-Boitrel,M.T., Solary,E. and Pommier,Y. (2001) Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. *Oncogene*, **20**, 1852–1859.
32. Jones,D.T., Ganeshaguru,K., Virchis,A.E., Folarin,N.I., Lowdell,M.W., Mehta,A.B., Prentice,H.G., Hoffbrand,A.V. and Wickremasinghe,R.G. (2001) Caspase 8 activation independent of Fas (CD95/APO-1) signaling

may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. *Blood*, **98**, 2800–2807.

33. Micheau,O., Solary,E., Hammann,A. and Dimanche-Boitrel,M.T. (1999) Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. *J. Biol. Chem.*, **274**, 7987–7992.

34. Safayhi,H., Mack,T. and Ammon,H.P. (1991) Protection by boswellic acids against galactosamine/endotoxin-induced hepatitis in mice. *Biochem. Pharmacol.*, **41**, 1536–1537.

35. Ghosh,J. and Myers,C.E. (1998) Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. *Proc. Natl Acad. Sci. USA*, **95**, 13182–13187.

36. Avis,I., Hong,S.H., Martinez,A., Moody,T., Choi,Y.H., Trepel,J., Das,R., Jett,M. and Mulshine,J.L. (2001) Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. *FASEB J.*, **15**, 2007–2009.

37. Hoernlein,R.F., Orlikowsky,T., Zehrer,C., Niethammer,D., Sailer,E.R., Simmet,T., Dannecker,G.E. and Ammon,H.P. (1999) Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. *J. Pharmacol. Exp. Ther.*, **288**, 613–619.

38. Syrovets,T., Buchele,B., Gedig,E., Slupsky,J.R. and Simmet,T. (2000) Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha. *Mol. Pharmacol.*, **58**, 71–81.

39. Altmann,A., Fischer,L., Schubert-Zsilavecz,M., Steinhiber,D. and Werz,O. (2001) Boswellic acids activate-p42(MAPK) and p38 MAPK and stimulate Ca2+ mobilization. *Biochem. Biophys. Res. Commun.*, **290**, 185–190.

40. He,Q., Lee,D.I., Rong,R., Yu,M., Luo,X., Klein,M., El-Deiry,W.S., Huang,Y. Hussain,A. and Sheikh,M.S. (2002) Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. *Oncogene*, **21**, 2623–2633.

41. Lin,S.Y., Chang,Y.T., Liu,J.D., Yu,C.H., Ho,Y.S., Lee,Y.H. and Lee,W.S. (2001) Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells. *Mol. Carcinogen.*, **32**, 73–83.

42. Kauffman,J. and Van Dam,J. (1998) Mechanism underlying NSAID-mediated inhibition of colorectal tumorigenesis. *Gastroenterology*, **115**, 1599–1600.

43. Shiff,S.J. and Rigas,B. (1998) Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. *Gastroenterology*, **113**, 1992–1998.

44. Fennerty,M.B. (2001) NSAID-related gastrointestinal injury. Evidence-based approach to a preventable complication. *Postgrad. Med.*, **110**, 87–88, 91–94.

45. Cuzzolin,L., Dal Cere,M. and Fanos,V. (2001) NSAID-induced nephrotoxicity from the fetus to the child. *Drug Saf.*, **24**, 9–18.

46. Gupta,I., Gupta,V., Parihar,A., Gupta,S., Ludtke,R., Safayhi,H. and Ammon,H.P. (1998) Effects of *Boswellia serrata* gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. *Eur. J. Med. Res.*, **3**, 511–514.

47. Liu,J-J., Nilsson,Å., Oredsson,S., Badmaev,V. and Duan,R.-D. (2002) Keto-and acetyl-keto-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via a caspase-8 dependent pathway. *Intl J. Mol. Med.*, **10**, 501–505.

48. Wang,S.Y., Chen,L.Y., Tsai,T.F., Su,T.S., Choo,K.B. and Ho,C.K. (1996) Constitutive production of colony-stimulating factors by human hepatoma cell lines: possible correlation with cell differentiation. *Exp. Hematol.*, **24**, 437–444.